Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.